Navidea Biopharmaceuticals - Case Summary

Business Description Navidea Biopharmaceuticals, Inc. ("Navidea" or the "Debtor") is a pre-revenue research and development company focused on precision medi...

Business Description

Navidea Biopharmaceuticals, Inc. ("Navidea" or the "Debtor") is a pre-revenue research and development company focused on precision medicine, specializing in immuno-targeted diagnostics and therapeutics for diseases such as cancer and autoimmune disorders.

Historically, Navidea was a leader in developing radiopharmaceutical products, most notably Lymphoseek®, a first-of-its-kind, receptor-targeted agent for lymphatic mapping used to diagnose and stage metastatic cancers.
Following the 2017 sale of its Lymphoseek® assets to Cardinal Health, the Debtor transitioned its focus to developing an "Improved API" (Active Pharmaceutical Ingredient). This new API is designed to serve as a generic competitor to Lymphoseek® and is described by the company as superior to the original formulation sold to Cardinal Health.

The Debtor does not currently generate revenue and is entirely focused on its R&D pipeline. To date, Navidea has invested over six years and approximately $4.1 million in the development of the Improved API, with an estimated $400,000 in additional funding required to complete the process. In 2024, the company generated $1.5 million from the one-time sale of a pre-clinical asset, NAV4694. The company's pipeline also includes other diagnostic agents, such as AZD4694 and RIGScan.

Corporate History

Navidea's corporate history is defined by the development and subsequent sale of its flagship product, Lymphoseek®, and its recent transition to a pre-revenue R&D entity.

Sale of Lymphoseek® to Cardinal Health

In need of liquidity to fund operations and address mounting legal fees, Navidea sold its North American assets related to Lymphoseek® to Cardinal Health in a transaction that closed in March 2017. The sale included the Lymphoseek® trademark and rights to key intellectual property, including the Vera Patents (which expired in May 2025).
Under the terms of the sale, Navidea retained its business outside of North America and was subject to a five-year non-compete restriction in the field of Lymphatic Mapping, which expired in March 2022.
Concurrent with the sale, the parties entered into a License Back Agreement, which authorized Navidea to compete non-exclusively outside of North America and assigned any improvements to the API made by Navidea back to the company.
Cardinal Health has since successfully commercialized Lymphoseek® in North America, with the market estimated to have exceeded $100 million in annual sales in 2023.

Post-Sale Strategy and Improved API Development

In February 2018, Navidea began developing its Improved API for therapeutic purposes, as permitted under its agreements with Cardinal Health.
The company engaged Corden Pharma Switzerland, LLC ("Corden") to assist with the development and entered into a manufacturing contract in February 2018, which was later expanded to a commercial supply Master Services Agreement in August 2021.

Public Listing and Deregistration

Navidea was previously a publicly traded company on the NYSE American exchange under the ticker symbol NAVB.
In June 2023, the company received a notice of non-compliance from the NYSE due to its low trading price. After failing to regain compliance, the company's stock was delisted in October 2023 and began trading on over-the-counter (OTC) markets.
Following the delisting, Navidea filed a Form 15 with the SEC to deregister its stock and suspend its public reporting obligations, a move management estimated would save the company over $2 million annually in administrative costs.

Historical Financing

To fund the costly development of Lymphoseek®, Navidea historically raised capital through a series of significant debt facilities, including a $50 million credit facility with Platinum-Montaur (2012), a $25 million loan with GECC and MidCap (2013), a $30 million loan with Oxford Finance (2014), and a $50 million loan with Capital Royalty Partners II, L.P. ("CRG") (2015).

Operations Overview

As a debtor-in-possession, Navidea's operations have been significantly limited by its financial condition. The company is a Delaware corporation with a minimal workforce consisting of one full-time employee (the CFO) and two part-time employees (a chemist and a director of science). If adequately funded, this team would focus on advancing the development of several pre-clinical therapeutic drugs for cancer and auto-immune disorders.

The Debtor relies heavily on its relationship with third parties in Europe, particularly Corden in Switzerland, for the development of its Improved API.

Corporate and Ownership Structure

Navidea has two wholly-owned subsidiaries, Navidea Biopharmaceuticals Europe Limited and Navidea Biopharmaceuticals Limited, as well as a majority-owned subsidiary, Macrophage Therapeutics, Inc. ("MT").
John Kimball Scott, Jr., who became a director in 2021, is the company's majority owner, holding 54.92% of the outstanding common stock as well as significant positions in the company's convertible debt and warrants.

Prepetition Obligations

As of the Petition Date, Navidea has approximately $7.8 million in secured debt and $2.5 million in unsecured debt.

Secured Debt

The company's sole secured creditor is its majority owner, John Kimball Scott, Jr., who is owed approximately $7.8 million across four separate loan facilities:
- Secured Term Loan (April 2022): ~$1.6 million outstanding.
- Secured Convertible Promissory Note (Nov. 2023): ~$885,000 outstanding.
- Amended and Restated Senior Secured Bridge Loan (March 2024): ~$3.4 million outstanding.
- Secured Revolving Demand Loan (Jan. 2025): ~$2.0 million outstanding.

Unsecured Debt

The Debtor has approximately $2.5 million in unsecured debt owed to non-insiders, consisting primarily of trade vendor and legal services claims.

Key Executory Contracts and Leases

Navidea is a party to one lease for executive office space in Columbus, OH.
The company maintains two major executory contracts with Cardinal Health and Corden.
- Pursuant to a January 2021 API Development Funding and Access Agreement, Navidea granted Cardinal Health rights to access a supply of the Improved API from Corden in exchange for financial assistance to complete its development.

Events Leading to Bankruptcy

Navidea's financial distress is the result of protracted and costly litigation, failed clinical trials, and key strategic decisions that limited long-term revenue. Facing threats of an involuntary bankruptcy petition from creditors, the Debtor filed for Chapter 11 Subchapter V protection on Oct. 1, 2025, to restructure its balance sheet and operations.

Protracted and Costly Litigation

CRG Litigation: A primary driver of the company's financial decline was years of litigation with its former lender, CRG.
- In April 2016, CRG declared a technical default on its $50 million loan, initiating lawsuits in Texas and Ohio. The pressure from this litigation was a key impetus for the 2017 sale of Lymphoseek® assets to Cardinal Health.
- While a 2017 Global Settlement Agreement capped Navidea's liability at $66 million, the company was ultimately subject to judgments totaling approximately $9.6 million across two separate lawsuits filed by CRG. The company states it was never able to financially recover from the cost of defending these actions and satisfying the judgments.
Goldberg Litigation: In 2019, Navidea sued its former CEO, Dr. Michael Goldberg, for allegedly breaching his separation agreement by improperly transferring assets from the company's subsidiary, MT. This led to years of expensive litigation and counterclaims, which culminated in a December 2024 jury trial verdict in favor of Navidea. Dr. Goldberg is currently appealing the decision.
Other Lawsuits: The company's cash position continues to be drained by several other pending lawsuits, including a shareholder derivative action and a second suit brought by Dr. Goldberg, both in Delaware.

Operational and Financial Setbacks

Forgone Royalties: Following the sale to Cardinal Health, Navidea's management elected to receive a discounted, lump-sum cash payment of $17 million in lieu of future royalties on Lymphoseek® sales, which were estimated at $165 million. This decision provided short-term liquidity but eliminated a significant long-term revenue stream as Lymphoseek® achieved commercial success.
Failed Clinical Trials: Navidea invested millions of dollars in clinical trials for a rheumatoid arthritis diagnostic. The program was discontinued in July 2024 after an exploratory analysis failed to demonstrate clinical efficacy, resulting in a total loss of the company's investment.

External Pressures and Path to Chapter 11

The company's reliance on international third parties exposed it to financial strain from global supply chain disruptions and energy market volatility related to the conflict in Ukraine.
With its liquidity depleted by litigation and failed R&D, Navidea faced increasing pressure from creditors, including threats to file an involuntary bankruptcy petition, which ultimately prompted the voluntary Chapter 11 filing.